MMP2 activity is critical for TGFβ2-induced matrix contraction-implications for fibrosis

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 7, 2012, Pages 4085-4098

  Eldred, Julie A ^a   Hodgkinson, Lisa M ^a   Dawes, Lucy J ^a   Reddan, John R ^b   Edwards, Dylan R ^a   Wormstone, I Michael ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GELATINASE A; ILOMASTAT; MATRIX METALLOPROTEINASE 14; NEUTRALIZING ANTIBODY; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA2; RNA; SCLEROPROTEIN;

ARTICLE; BIOTRAK ASSAY; CAPSULAR BAG ANALYSIS; CATARACT; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MATRIX CONTRACTION; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PATCH CONTRACTION ASSAY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TAQMAN ANALYSIS; UPREGULATION; VALIDATION PROCESS; WESTERN BLOTTING; BIOSYNTHESIS; CELL LINE; COMPARATIVE STUDY; DRUG EFFECT; ENZYMOLOGY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LENS CAPSULE; METABOLISM; PRENATAL DEVELOPMENT; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; LENS CAPSULE, CRYSTALLINE; MATRIX METALLOPROTEINASE 2; MICROARRAY ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84871890588     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9457     Document Type: Article

References (59)

1. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J. 2004;18:816-827.
2. Wormstone IM. Posterior capsule opacification: a cell biological perspective. Exp Eye Res. 2002;74:337-347.
3. Eldred JA, Dawes LJ, Wormstone IM. The lens as a model for fibrotic disease. Philos Trans R Soc Lond B Biol Sci. 2011;366: 1301-1319.
4. van Bree MCJ, van der Meulen IJE, Franssen L, et al. Imaging of forward light-scatter by opacified posterior capsules isolated from pseudophakic donor eyes. Invest Ophthalmol Vis Sci. 2011;52:5587-5597.
5. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull WHO. 2004;82:844-851.
6. Taylor HR. Cataract: how much surgery do we have to do?. Br J Ophthalmol. 2000;84:1-2.
7. Laurell CG, Zetterstrom C. Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br J Ophthalmol. 2002;86:1380-1384.
8. Moisseiev J, Bartov E, Schochat A, Blumenthal M. Long-term study of the prevalence of capsular opacification following extracapsular cataract-extraction. J Cataract Refract Surg. 1989;15:531-533.
9. Sime PJ, O'Reilly KMA. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol. 2001;99:308-319.
10. Wormstone IM, Anderson IK, Eldred JA, Dawes LJ, Duncan G. Short-term exposure to transforming growth factor beta induces long-term fibrotic responses. Exp Eye Res. 2006;83: 1238-1245.
11. Wormstone IM, Wang LX, Liu CSC. Posterior capsule opacification. Exp Eye Res. 2009;88:257-269.
12. Schlotzer-Schrehardt U, Zenkel M, Kuchle M, Sakai LY, Naumann GO. Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res. 2001;73:765-780.
13. Ohta K, Yamagami S, Taylor AW, Streilein JW. IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 2000; 41:2591-2599.
14. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase- 9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14:163-176.
15. Frazier WA. Thrombospondins. Curr Opin Cell Biol. 1991;3: 792-799.
16. Wallentin N, Wickstrom K, Lundberg C. Effect of cataract surgery on aqueous TGF-beta and lens epithelial cell proliferation. Invest Ophthalmol Vis Sci. 1998;39:1410-1418.
17. Liu CSC, Wormstone IM, Duncan G, Marcantonio JM, Webb SF, Davies PD. A study of human lens cell growth in vitro-a model for posterior capsule opacification. Invest Ophthalmol Vis Sci. 1996;37:906-914.
18. Wormstone IM, Tamiya S, Anderson I, Duncan G. TGF-beta 2- induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci. 2002; 43:2301-2308.
19. Hales AM, Schulz MW, Chamberlain CG, McAvoy JW. TGF-beta- 1 induces lens cells to accumulate alpha-smooth muscle actin, a marker for subcapsular cataracts. Curr Eye Res. 1994;13: 885-890.
20. Wride MA, Geatrell J, Guggenheim JA. Proteases in eye development and disease. Birth Defects Res C Embryo Today. 2006;78:90-105.
21. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases - Structure, function, and biochemistry. Circ Res. 2003;92:827-839.
22. Mandal M, Mandal A, Das S, Chakraborti T, Chakraborti S. Clinical implications of matrix metalloproteinases. Mol Cell Biochem. 2003;252:305-329.
23. Dwivedi DJ, Pino G, Banh A, et al. Matrix metalloproteinase inhibitors suppress transforming growth factor-beta-induced subcapsular cataract formation. Am J Pathol. 2006;168:69-79.
24. Hodgkinson LM, Duncan G, Wang LX, Pennington CJ, Edwards DR, Wormstone IM. MMP and TIMP expression in quiescent, dividing, and differentiating human lens cells. Invest Ophthalmol Vis Sci. 2007;48:4192-4199.
25. Seiki M. Membrane-type matrix metalloproteinases. APMIS. 1999;107:137-143.
26. Kandasamy AD, Chow AK, Ali MA, Schulz R. Matrix metalloproteinase- 2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res. 2010;85:413-423.
27. Wormstone IM, Tamiya S, Eldred JA, et al. Characterisation of TGF-beta 2 signalling and function in a human lens cell line. Exp Eye Res. 2004;78:705-714.
28. Dawes LJ, Eldred JA, Anderson IK, et al. TGF beta-induced contraction is not promoted by fibronectin-fibronectin receptor interaction, or alpha SMA expression. Invest Ophthalmol Vis Sci. 2008;49:650-661.
29. Dawes LJ, Elliott RM, Reddan JR, Wormstone YM, Wormstone IM. Oligonucleotide microarray analysis of human lens epithelial cells: TGF beta regulated gene expression. Mol Vis. 2007;13:1181-1197.
30. Nuttall RK, Pennington CJ, Taplin J, et al. Elevated membranetype matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res. 2003;1:333-345.
31. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J. 1997;16:7032-7044.
32. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002;13:2600-2610.
33. Khalil N, O'Connor R. Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. Can Med Assoc J. 2004;171:153-160.
34. Krieg T, Takehara K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology. 2009;48:14-18.
35. Roberts AB, McCune BK, Sporn MB. TGF-beta-regulation of extracellular-matrix. Kidney Int. 1992;41:557-559.
36. Jenkins G. The role of proteases in transforming growth factorbeta activation. Int J Biochem Cell Biol. 2008;40:1068-1078.
37. Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J. 2006;20:1898-1900.
38. Dehm P, Kefalides NA. The collagenous component of lens basement membrane. The isolation and characterization of an alpha chain size collagenous peptide and its relationship to newly synthesized lens components. J Biol Chem. 1978;253: 6680-6686.
39. Wederell ED, de Iongh RU. Extracellular matrix and integrin signaling in lens development and cataract. Semin Cell Dev Biol. 2006;17:759-776.
40. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF beta activation. J Cell Sci. 2003;116:217-224.
41. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int. 1997;51:1376-1382.
42. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8:221-233.
43. Boyd PJ, Doyle J, Gee E, Pallan S, Haas TL. MAPK signaling regulates endothelial cell assembly into networks and expression of MT1-MMP and MMP-2. Am J Physiol Cell Physiol. 2005; 288:C659-C668.
44. Hernandez-Barrantes S, Toth M, Bernardo MM, et al. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem. 2000;275:12080-12089.
45. Wang ZP, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem. 2000; 275:26411-26415.
46. Morrison CJ, Butler GS, Bigg HF, Roberts CR, Soloway PD, Overall CM. Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J Biol Chem. 2001;276:47402-47410.
47. Ruangpanit N, Price JT, Holmbeck K, et al. MT1-MMPdependent and -independent regulation of gelatinase a activation in long-term, ascorbate-treated fibroblast cultures: regulation by fibrillar collagen. Exp Cell Res. 2002;272:109-118.
48. Wong TT, Daniels JT, Crowston JG, Khaw PT. MMP inhibition prevents human lens epithelial cell migration and contraction of the lens capsule. Br J Ophthalmol. 2004;88:868-872.
49. Seomun Y, Kim J, Lee EH, Joo CK. Overexpression of matrix metalloproteinase-2 mediates phenotypic transformation of lens epithelial cells. Biochem J. 2001;358:41-48.
50. Tholozan FMD, Gribbon C, Li Z, et al. IFGF-2 release from the lens capsule by MMP-2 maintains lens epithelial cell viability. Mol Biol Cell. 2007;18:4222-4231.
51. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein- 3 in dermal fibroblast-cultures. J Biol Chem. 1994;269: 25742-25746.
52. Cerra A, Mansfield KJ, Chamberlain CG. Exacerbation of TGFbeta- induced cataract by FGF-2 in cultured rat lenses. Mol Vis. 2003;9:689-700.
53. Ishida I, Saika S, Okada Y, Ohnishi Y. Growth factor deposition in anterior subcapsular cataract. J Cataract Refract Surg. 2005;31:1219-1225.
54. Wormstone IM, Del Rio-Tsonis K, McMahon G, et al. FGF: an autocrine regulator of human lens cell growth independent of added stimuli. Invest Ophthalmol Vis Sci. 2001;42:1305-1311.
55. Maloof AJ, Pandey SK, Neilson G, Milverton EJ. Selective death of lens epithelial cells using demineralized water and Triton X- 100 with PerfectCapsule sealed capsule irrigation: a histological study in rabbit eyes. Arch Ophthalmol. 2005;123:1378-1384.
56. Duncan G, Wang L, Neilson GJ, Wormstone IM. Lens cell survival after exposure to stress in the closed capsular bag. Invest Ophthalmol Vis Sci. 2007;48:2701-2707.
57. Behar-Cohen FF, David T, D'Hermies F, et al. In vivo inhibition of lens regrowth by fibroblast growth factor 2-saporin. Invest Ophthalmol Vis Sci. 1995;36:2434-2448.
58. Duncan G, Wormstone IM, Liu CS, Marcantonio JM, Davies PD. Thapsigargin-coated intraocular lenses inhibit human lens cell growth. Nat Med. 1997;3:1026-1028.
59. Morarescu D, West-Mays JA, Sheardown HD. Effect of delivery of MMP inhibitors from PDMS as a model IOL material on PCO markers. Biomaterials. 2010;31:2399-2407.